<DOC>
	<DOCNO>NCT01905124</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-masked , placebo-controlled study subject active , sight-threatening , noninfectious intermediate posterior uveitis .</brief_summary>
	<brief_title>Safety &amp; Efficacy CF101 Subjects With Uveitis</brief_title>
	<detailed_description>This Phase 2 , randomize , double-masked , placebo-controlled study adult male female , age 18 year , active , sight-threatening , noninfectious intermediate posterior uveitis . Subjects randomly assign receive CF101 1 mg match placebo tablet 2:1 ratio orally every 12 hour 24 week . At Screening Visit ( perform within 4 week prior Baseline ) , subject provide write informed consent complete medical history , medication history , physical examination , weight , sit blood pressure , pulse rate , temperature , electrocardiogram ( ECG ) , clinical laboratory test , ophthalmologic examination , include biomicroscopy grade uveitis activity . For assessment uveitis activity response treatment , fundus photography obtain accord standardized procedure interpret Uveitis Photograph Reading Center . Subjects successfully qualify begin dose CF101 1 mg placebo , take orally every 12 hour 24 week . At Baseline Visit , PBMC sample obtain assessment A3AR expression level . Subjects return safety efficacy assessments new supply study medication Weeks 2 , 4 , 8 , 12 , 16 , 20 , final assessment discharge Week 24 . A telephone call subject make Week 26 , purpose collect information adverse event ( AEs ) concomitant medication . During course trial , concomitant use intraocular posterior subtenon corticosteroid , intravitreal injection ( include limited steroid anti-vascular endothelial growth factor ) , systemic corticosteroid dose &gt; 20 mg/day prednisone equivalent , monoclonal antibody therapy prohibit . Systemic corticosteroid immunosuppressive regimen must remain stable throughout course trial .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>1 . Male female , 18 year age ; 2 . Diagnosis active , sightthreatening , noninfectious intermediate posterior uveitis , determine Standardization Uveitis Nomenclature ( SUN ) Working Group Criteria . 3 . Vitreous haze least 1 eye ( `` study eye '' ) ≥Grade 3 `` Miami Scale '' Screening Visit , confirm Uveitis Photograph Reading Center ; , 4 . Best correct visual acuity ( BCVA ) poorer see eye 1.3 logarithm minimum angle resolution ( logMAR ) good Early Treatment Diabetic Retinopathy Study ( ETDRS ; equivalent 20/400 ) Screening ; 5 . Requires , judgment Investigator , systemic therapy treat uveitis ; 6 . No plan elective ocular surgery trial duration ; 10 . Ability understand provide write informed consent . 1 . Primary diagnosis anterior uveitis ; 2 . Uveitis infectious etiology ; 3 . Presence chorioretinal scar highly suspicious ocular toxoplasmosis ; 4 . Confirmed suspected uveitis traumatic etiology ; 5 . Clinically suspect confirmed central nervous system ocular lymphoma ; 6 . Presence form ocular malignancy either eye include choroidal melanoma ; 7 . Corneal lens opacity obscure ocular medium vitreous haze upon enrollment reliable clinical evaluation grade posterior segment perform ; 8 . Pupillary dilation inadequate quality fundus photography ; 9 . Uncontrolled glaucoma ocular hypertension either eye , define intraocular pressure ( IOP ) &gt; 21 mm Hg medical therapy ; 10 . Chronic hypotony ( IOP &lt; 6 mm Hg ) either eye ; 11 . Presence ocular implantable steroideluting device ; 12 . Ocular injection corticosteroid within 3 month prior Baseline ; 13 . Use Retisert within 6 month prior baseline ; 14 . Use follow within 90 day prior Baseline anticipate use either eye trial : 1 . Intravitreal injection ( include limited steroid antivascular endothelial growth factor ) , 2 . Posterior subtenon steroid ; 15 . YAG capsulotomy within 30 day prior Day 1 study eye ; 16 . History herpetic infection study eye adnexa ; 17 . Oral corticosteroid dose &gt; 20 mg/day prednisone equivalent ; 18 . Oral corticosteroid dose change within 2 week prior screen , expect change study ; 19 . Systemic immunosuppressive agent dose change within 2 week prior screen ; 20 . Treatment systemic monoclonal antibody within long 1 month 5 serum halflives , prior screen ; 21 . Diagnosis history Behçet 's Disease ; 22 . Any significant ocular disease could compromise vision either eye , include limited : 1 . Diabetic retinopathy : proliferative diabetic retinopathy nonproliferative diabetic retinopathy compromise vision , 2 . Wet agerelated macular degeneration , 3 . Myopic degeneration active subfoveal choroidal neovascularization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Intermediate uveitis</keyword>
	<keyword>Posterior uveitis</keyword>
</DOC>